

ARTICLE NAVIGATION

ORAL PRESENTATIONS - PROFFERED ABSTRACTS | APRIL 25 2025

Abstract CT010: Phase I dose-escalation and expansion study of JS107, a claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC), as monotherapy or in combination for patients (pts) with advanced solid tumors

FREE

Rui-Hua Xu; Dan-Yun Ruan; Rong-Bo Lin; Jian-Zhen Shan; Peng Nie; Ying-Hua Ji; Jing Wang; Yu Cao; Fu-Nan Liu; Jie-Er Ying; Li Liu; Tao Zhang; Hui-Ting Xu; Yan-Qiao Zhang; Wen-Can Song; Jin Xia; Wen-Feng Li; Zhi-Ye Zhang; Jian Shi; Ming-Xia Wang; Long Wu; Yan-Yan Lu; Xiao Zhang; Yan-Yan Hu; Yong-Dong Zhang

[+ Author & Article Information](#)

Cancer Res (2025) 85 (8_Supplement_2): CT010.

<https://doi.org/10.1158/1538-7445.AM2025-CT010>

Split-Screen

Share ▾

Tools ▾

Versions ▾

Abstract

Background:

JS107 is a monomethyl auristatin E conjugated, CLDN18.2 specific ADC. JS107 exhibited potent anti-tumor activities in preclinical studies with a tolerable safety profile. Here we report the safety and efficacy results of JS107 monotherapy or in combination for pts with advanced solid tumors from the first-in-human phase 1 trial (NCT05502393).

Methods:

In Part A of the study, pts with advanced solid tumors refractory to standard therapies were treated with JS107 at 0.15-3.5 mg/kg Q3W during dose escalation and CLDN18.2+ pts were treated with JS107 at 2.0 and 3.0 mg/kg Q3W during dose expansion. In Part B of the study, pts with CLDN18.2+, HER2-negative, previously untreated, advanced gastric or gastroesophageal junction cancer (GC/GEJ) were treated with JS107 combined with toripalimab (240 mg Q3W) and XELOX (capecitabine and oxaliplatin), in dose escalation (JS107 at 2.0-3.0 mg/kg Q3W) and expansion (JS107 at 2.0 mg/kg Q3W) phases. The primary endpoint was safety. Secondary endpoints included efficacy and pharmacokinetics (PK).

[Skip to Main Content](#)

Results:

As of January 7, 2025, 63 pts were enrolled in Part A (22 in dose escalation and 41 in dose expansion) and 27 enrolled in Part B (9 in dose escalation and 18 in dose expansion). The

maximum tolerated dose was not reached for JS107 monotherapy and was 2.5 mg/kg for combination treatment. Grade 3 and above treatment-related adverse events (TRAEs) occurred in 47.6% pts in Part A and 40.7% pts in Part B. The most frequent grade 3 and above TRAE was neutropenia (22.2%) in Part A and thrombocytopenia (18.5%) in Part B. Among pts with CLDN18.2-high (defined as $\geq 20\%$ of tumor cells with $\geq 2+$ staining intensity) GC/GEJ who received JS107 monotherapy at 2.0-3.0 mg/kg (n=24), the objective response rate (ORR) was 34.8% (8/23, 95%CI 16.4-57.3) and median progression-free survival was 4.11 months (95%CI 3.15-9.63). Among efficacy evaluable pts with CLDN18.2-high GC/GEJ in Part B (n=14), the ORR was 78.6% (11/14, 95%CI 49.2-95.3). A positive association between CLDN18.2 expression level and efficacy was observed in Part A and Part B. PK analysis showed a dose-dependent ADC and total antibody exposure at doses of 0.15-3.5 mg/kg. JS107 elimination half-life was 4.41-6.96 days at doses of 2.0-3.5 mg/kg, with no obvious accumulation observed after multiple dosing.

Conclusions:

JS107 monotherapy or in combination with toripalimab and XELOX showed promising efficacy in pts with CLDN18.2-high advanced GC/GEJ with a manageable safety profile. The clinical benefit of CLDN18.2 ADC combination treatment was thus demonstrated for the first time. Further clinical development of JS107 in CLDN18.2+ advanced solid tumors is warranted.

Citation Format:

Rui-Hua Xu, Dan-Yun Ruan, Rong-Bo Lin, Jian-Zhen Shan, Peng Nie, Ying-Hua Ji, Jing Wang, Yu Cao, Fu-Nan Liu, Jie-Er Ying, Li Liu, Tao Zhang, Hui-Ting Xu, Yan-Qiao Zhang, Wen-Can Song, Jin Xia, Wen-Feng Li, Zhi-Ye Zhang, Jian Shi, Ming-Xia Wang, Long Wu, Yan-Yan Lu, Xiao Zhang, Yan-Yan Hu, Yong-Dong Zhang. Phase I dose-escalation and expansion study of JS107, a claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC), as monotherapy or in combination for patients (pts) with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT010.

[View Metrics](#)

Citing Articles Via

[Google Scholar](#)

Email Alerts

[Article Activity Alert](#)

[eTOC Alert](#)

Latest News

[Deploying AI to Better Suss Out HER2 Status](#)

[New Ovarian Cancer Combo Shows Wider Promise](#)

[“Brain Fog” after CAR T May Be Reversible](#)

[View more recent articles >](#)

[Skip to Main Content](#)

Breaking

[PI3K Inhibitor Delays Chemotherapy Start](#)

Drug Combo Boosts Lung Cancer Survival

Genentech, Orionis to Stick Together with Deal on Glues

[View more recent articles >](#)

Research Watch

Ferroptosis Is Induced by Lysosomal Iron Activation in Cancer Cells

Common Blood Tests Predict CAR T-cell Therapy Response in Non-Hodgkin Lymphoma

Frequent Blood Donation Influences DNMT3A-Driven Clonal Hematopoiesis

[View more recent articles >](#)

Advertisement

Issues

Online First

Collections

News

Twitter

Online ISSN 1538-7445 **Print ISSN** 0008-5472

AACR Journals

Blood Cancer

Discovery

Cancer Discovery

Cancer

Epidemiology,

Biomarkers &

Prevention

[Skip to Main Content](#)

Cancer Immunology

Research

Cancer Prevention

Research

Cancer Research

Cancer Research

Communications

Clinical Cancer

Research

Molecular Cancer

Research

Molecular Cancer

Therapeutics



[Information on
Advertising & Reprints](#)

[Information for
Institutions/Librarians](#)

[RSS Feeds](#)

[Privacy Policy](#)

Copyright © 2025 by the American Association for Cancer Research.